PsyBio Therapeutics (PsyBio Therapeutics) Cash-to-Debt : 0.13 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is PsyBio Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PsyBio Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2023 was 0.13.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, PsyBio Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for PsyBio Therapeutics's Cash-to-Debt or its related term are showing as below:

PSYBF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 9.89 Max: No Debt
Current: 0.13

During the past 2 years, PsyBio Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 9.89.

PSYBF's Cash-to-Debt is ranked worse than
93.64% of 1540 companies
in the Biotechnology industry
Industry Median: 6.485 vs PSYBF: 0.13

PsyBio Therapeutics Cash-to-Debt Historical Data

The historical data trend for PsyBio Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

PsyBio Therapeutics Cash-to-Debt Chart

PsyBio Therapeutics Annual Data

Trend

Dec21

Dec22

Cash-to-Debt

No Debt

0.01

PsyBio Therapeutics Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash-to-Debt	Get a 7-Day Free Trial							4.39	1.05	0.01	0.72	0.13

Competitive Comparison of PsyBio Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, PsyBio Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PsyBio Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PsyBio Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where PsyBio Therapeutics's Cash-to-Debt falls into.

PsyBio Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

PsyBio Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.001	/	(0.135	+	0)
	=	0.01

PsyBio Therapeutics's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.012	/	(0.096	+	0)
	=	0.13

PsyBio Therapeutics (OTCPK:PSYBF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

PsyBio Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of PsyBio Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

PsyBio Therapeutics (PsyBio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PsyBio Therapeutics Corp (OTCPK:PSYBF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PSYB:Canada

Address

4400 Sample Road, Suite 138, Coconut Creek, FL, USA, 33073

Website

https://www.psybiolife.com

PsyBio Therapeutics Corp is a biotechnology company. The company is engaged in the development of drugs intended for the treatment of mental illness and neurological disorders.

PsyBio Therapeutics (PsyBio Therapeutics) Headlines

From GuruFocus

PsyBio Therapeutics to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th

By PRNewswire PRNewswire • 10-11-2021

PsyBio Announces Second Quarter Financial Results of Leo Acquisition Corp.

By GlobeNewswire GlobeNewswire • 03-02-2021

PsyBio Therapeutics Announces Uplisting to OTCQB Venture Market

By PRNewswire PRNewswire • 07-14-2021